Dry Eye Syndrome Market Size Study, by Type, Application, Region, Forecast 2017-2023

10/giu/2021 12:47:42 vinit sawant Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Electronic devices' escalated use has promoted the need for products to treat it, thus motivating the dry eye syndrome market. Reports created by MRFR detail the developments in the industry that can be expected in the market through the forecast period. By 2025, a 6.6% CAGR is estimated for the global market in the coming period.

The increased occurrence of infections has further created the dry eye syndrome market's potential in the impending period. Furthermore, the increased prevalence of diabetes is foreseen to create further opportunities for the dry eye syndrome market share in the forthcoming years.

Segmental Analysis

The segmental appraisal of the dry eye syndrome market is carried out on the basis of type, diagnosis, treatment, distribution channel, end user and region. The end users' segment of the dry eye syndrome market consists of clinics, home care, and hospitals. The distribution channel segment of the dry eye syndrome market consists of retail pharmacies, hospital pharmacies, and online pharmacies. The diagnosis segment of the dry eye syndrome market consists of eye exam and Schirmer test.   The dry eye syndrome market's treatment segment consists of serum eye drops, lubricant eye drops, nutritional supplements, surgery, and anti-inflammatory drugs segments. The type segment of the dry eye syndrome market consists of aqueous dry eye syndrome and evaporative dry eye syndrome. The regions included in the dry eye syndrome market are Europe, Asia Pacific, North America and other pivotal regions.

Competitive Analysis

The expansion of geographical footprint is estimated to tap into undiscovered segments is likely to have a favorable effect on the market developments. The effect of novelty and effective pricing policies will help the global market return to an optimal functioning level in the forecast period. The market is estimated to profit from the contenders' overall contribution who are having different fortes for growth. The buoyancy in market sentiment will act as a tool for future growth. The investment trend in the market is projected to display a trend of mergers and acquisitions. The role of government bodies is estimated to be essential to the development of the market. The presence of online channels is predicted to enhance the market's advancement in the upcoming years. The role of innovation is estimated to become even more important for progress as the market grows. The improvement in trade and distribution policies is further anticipated to motivate the market's development in the upcoming period.

Industry Updates:

Mar 2021 RegeneRx Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical business concentrating on tissue repair, protection, and regeneration, declared that the ARISE-3 Phase 3 clinical trial assessing RGN-259 eyedrops for the handling of dry eye syndrome did not meet its key outcome measures.   Though, effectiveness was seen in the enhancement of ocular grittiness, one of the pre-specified inferior symptom endpoints in the test.

Nov 2020 Wize Pharma's LO2A eye drops lead to clinically significant improvements in dry eye signs and indications in individuals with Sjögren's syndrome, topline outcomes from an investigative Phase 4 trial show. The medication continued to prove a good safety outline. It was discovered to be at least as effective at reducing corneal damage as the Systane Ultra UD over-the-counter lubricant, meeting the test's (NCT03319420) key objective.


blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl